methyl 1-(4-chlorobenzyl)-4-oxopiperidine-3-carboxylate | 1225491-24-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: methyl 1-(4-chlorobenzyl)-4-oxopiperidine-3-carboxylate
• 英文别名: Methyl 1-(4-chlorobenzyl)-4-oxo-3-piperidinecarboxylate；methyl 1-[(4-chlorophenyl)methyl]-4-oxopiperidine-3-carboxylate
• CAS: 1225491-24-6
• 化学式: C₁₄H₁₆ClNO₃
• 分子量: 281.739
• InChiKey: GECGMOGERGNOHU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  19
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 1-(4-chlorobenzyl)-4-oxopiperidine-3-carboxylate 在 sodium hydride 、 溶剂黄146 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 、 mineral oil 为溶剂， 反应 31.5h， 生成 3a-benzyl-5-(4-chlorobenzyl)-2-methyl-2,3a,4,5,6,7-hexahydro-3H-pyrazolo[4,3-c]pyridin-3-one
  参考文献：
  名称：

  Pyrazolo piperidine derivatives as NADPH oxidase inhibitors

  摘要：

  本发明涉及Formula (I)的吡唑哌啶衍生物、其药物组合物以及它们用于治疗和/或预防与烟酰胺腺嘌呤二核苷酸磷酸氧化酶（NADPH氧化酶）相关的疾病或症状。

  公开号：

  EP2361911A1
• 作为产物：
  描述：

  4-氧代哌啶-3-羰酸甲酯 盐酸盐 、 4-氯苄溴 在 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 16.0h， 以100%的产率得到methyl 1-(4-chlorobenzyl)-4-oxopiperidine-3-carboxylate
  参考文献：
  名称：

  [EN] PYRAZOLO PIPERIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS
  [FR] DÉRIVÉS PYRAZOLO PIPÉRIDINE EN TANT QU'INHIBITEURS DE LA NADP OXYDASE

  摘要：

  本发明涉及式（I）的吡唑吡啶衍生物，其制药组合物以及它们用于治疗和/或预防与尼古酰胺腺嘌呤二核苷酸磷酸氧化酶（NADPH氧化酶）相关的疾病或症状。

  公开号：

  WO2011101804A1

文献信息

• Pyrazolo Piperidine Derivatives as NADPH Oxidase Inhibitors
  申请人：Page Patrick

  公开号：US20120316163A1

  公开（公告）日：2012-12-13

  The present invention is related to pyrazolo piperidine derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).

  本发明涉及式(I)的吡唑啉哌啶衍生物、其制药组合物以及它们在治疗和/或预防与尼克酰胺腺嘌呤二核苷酸磷酸酰化酶（NADPH氧化酶）有关的疾病或症状方面的应用。
• Novel Hits in the Correction of ΔF508-Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Protein: Synthesis, Pharmacological, and ADME Evaluation of Tetrahydropyrido[4,3-<i>d</i>]pyrimidines for the Potential Treatment of Cystic Fibrosis
  作者：Elisabetta Pesci、Laura Bettinetti、Paola Fanti、Luis J. V. Galietta、Salvatore La Rosa、Letizia Magnoni、Nicoletta Pedemonte、Gian Luca Sardone、Laura Maccari

  DOI：10.1021/acs.jmedchem.5b00771

  日期：2015.12.24

  Cystic fibrosis (CF) is a lethal genetic disease caused by mutations of the gene encoding the cystic fibrosis transmembrane conductance regulator (CFTR) with a prevalence of the Delta F508 mutation. Whereas the detailed mechanisms underlying disease have yet to be fully elucidated, recent breakthroughs in clinical trials have demonstrated that CFTR dysfunction can be corrected by drug-like molecules. On the basis of this success, a screening campaign was carried out, seeking new drug-like compounds able to rescue Delta F508-CFTR that led to the discovery of a novel series of correctors based on a tetrahydropyrido[4,3-d]pyrimidine core. These molecules proved to be soluble, cell-permeable, and active in a disease relevant functional-assay. The series was then further optimized with emphasis on biological data from multiple cell systems while keeping physicochemical properties under strict control. The pharmacological and ADME profile of this corrector series hold promise for the development of more efficacious compounds to be explored for therapeutic use in CF.
• PYRAZOLO PIPERIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS
  申请人：GenKyoTex SA

  公开号：EP2536723B1

  公开（公告）日：2013-12-11
• US8865758B2
  申请人：——

  公开号：US8865758B2

  公开（公告）日：2014-10-21